Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Merrimack Pharmaceuticals Inc (MACK)
Merrimack Pharmaceuticals Inc (MACK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 180,731
  • Shares Outstanding, K 14,321
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,540 K
  • 60-Month Beta 1.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.74
Trade MACK with:

Options Overview Details

View History
  • Implied Volatility 11.95% ( -12.62%)
  • Historical Volatility 19.50%
  • IV Percentile 2%
  • IV Rank 6.19%
  • IV High 102.67% on 01/05/23
  • IV Low 5.96% on 09/28/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 1
  • Volume Avg (30-Day) 84
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 7,270
  • Open Int (30-Day) 7,155

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.01 +8.08%
on 11/08/23
12.99 -0.08%
on 12/07/23
+0.96 (+7.99%)
since 11/07/23
3-Month
12.00 +8.17%
on 11/07/23
12.99 -0.08%
on 12/07/23
+0.71 (+5.79%)
since 09/07/23
52-Week
10.10 +28.51%
on 12/22/22
13.15 -1.29%
on 05/10/23
+1.09 (+9.17%)
since 12/07/22

Most Recent Stories

More News
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm

VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial...

AAPL : 194.90 (+1.34%)
NYT : 47.47 (+0.42%)
ONCY : 1.3999 (+2.18%)
ONC.TO : 1.89 (+0.53%)
MACK : 12.98 (+2.85%)
INCY : 54.75 (-1.21%)
MRTX : 56.64 (-0.02%)
BNTX : 101.14 (-0.20%)
Pancreatic Cancer Battle Boosted by $200M VC Firm

/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...

ONC.TO : 1.89 (+0.53%)
ONCY : 1.3999 (+2.18%)
MACK : 12.98 (+2.85%)
INCY : 54.75 (-1.21%)
MRTX : 56.64 (-0.02%)
BNTX : 101.14 (-0.20%)
Pancreatic Cancer Battle Boosted by $200M VC Firm

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END

AAPL : 194.90 (+1.34%)
ONCY : 1.3999 (+2.18%)
ONC.TO : 1.89 (+0.53%)
MACK : 12.98 (+2.85%)
INCY : 54.75 (-1.21%)
MRTX : 56.64 (-0.02%)
BNTX : 101.14 (-0.20%)
Merrimack Reports First Quarter 2023 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 31, 2023.

MACK : 12.98 (+2.85%)
Merrimack Reports Full Year 2022 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, 2022.

MACK : 12.98 (+2.85%)
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “ Company ” or “ Merrimack ”), announced today that its Board of Directors (the “ Board ”) has extended the Section 382 net operating loss...

MACK : 12.98 (+2.85%)
The Zacks Analyst Blog Highlights Merrimack Pharmaceuticals, Moderna and Seagen

Highlights Merrimack Pharmaceuticals, Moderna and Seagen are included in this Analyst Blog.

MRNA : 79.92 (-0.84%)
SGEN : 218.51 (+1.26%)
MACK : 12.98 (+2.85%)
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More

Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.

MRNA : 79.92 (-0.84%)
SGEN : 218.51 (+1.26%)
MACK : 12.98 (+2.85%)
BCLI : 0.2553 (-14.13%)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)...

ONCY : 1.3999 (+2.18%)
ONC.TO : 1.89 (+0.53%)
SGEN : 218.51 (+1.26%)
MRTX : 56.64 (-0.02%)
AMGN : 272.81 (+1.28%)
MACK : 12.98 (+2.85%)
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –November 15, 2022 – USA News Group  –  Roughly five years after selling its flagship cancer asset Onivyde from to French...

ONCY : 1.3999 (+2.18%)
ONC.TO : 1.89 (+0.53%)
SGEN : 218.51 (+1.26%)
MRTX : 56.64 (-0.02%)
AMGN : 272.81 (+1.28%)
MACK : 12.98 (+2.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 13.12
2nd Resistance Point 13.01
1st Resistance Point 12.82
Last Price 12.98
1st Support Level 12.52
2nd Support Level 12.41
3rd Support Level 12.22

See More

52-Week High 13.15
Last Price 12.98
Fibonacci 61.8% 11.98
Fibonacci 50% 11.63
Fibonacci 38.2% 11.27
52-Week Low 10.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar